COMPOUND RECORD / CEREBROTEIN-HYDROLYSATE-I

Cerebrotein Hydrolysate-IЦеребропротеиновый гидролизат I

PerformanceStressRecovery

Source linked

01 / OVERVIEW

About Cerebrotein Hydrolysate-I

Names in this research collection

CH-1 · Cerebrotein hydrolysate 1

A distinct brain hydrolysate used in research to identify and evaluate candidate constituent peptides. Identity with PPK-V has not been established.

Research background

A distinct brain hydrolysate used in research to identify and evaluate candidate constituent peptides. Identity with PPK-V has not been established.

What the studies found

Animal research · 2023

Who or what was studiedExperimental rat pharmacokinetics and cell/transport assays.

Reported finding

Pep72 had very low measured blood–brain barrier permeability. The authors identified 11 main metabolites, including PGGDL and EPPTVPGGDL.

Pep72 permeability: Very low in the model usedThe peptide was not identified as an efflux transporter substrate.
Metabolites: 11 major structures identifiedPGGDL and EPPTVPGGDL were prominent products.
Exposure details: Study-specific doses require the complete methodsNo dosing equivalence to Cortexin or PPK-V.

All reported results & study design →

Methods, dose & source notes

Study of this preparation · Original indexed publication, PMID 37758480

Results concern one hydrolysate and its candidate metabolites. Similar molecular mass alone does not support a formulation match.

Cerebrotein Hydrolysate-I candidate peptide Pep72 ↗

These highlights cover selected studies. Open a source for its methods, reported doses and full context.

Compound class: Brain-derived peptide preparation
Research collection: Actoprotection & occupational pharmacology · editorial grouping
Research institutions: No institutional affiliation recorded
Source review: Review dates and the material assessed are listed with each publication below.

02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research The indexed source concerns preclinical experiments.
Study methods Peptide identification and experimental pharmacokinetics.
Independent replication Independent replication is not established in the linked sources.
Source access Original sources and the exact review scope are linked below.
Safety evidence The linked experiments do not establish a safe human performance regimen.

Open a topic for the evidence assessment.

More findings, background and history

EVIDENCE REVIEW / 6 OCTOBER 2026

Outstanding review questions

Appraise original methods and replication; keep animal and cell findings separate from unestablished human benefit and safety.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Publication records can share participants. Source counts are not trial counts.

Browse original study records ↗

03 / SOURCE RECORDS

Linked sources

Explore the research map and unresolved leads ↗

2023 · Cerebrotein Hydrolysate-I candidate peptide Pep72Pep72 permeability: Very low in the model used

2023Animal / experimentalEnglish abstract

Cerebrotein Hydrolysate-I candidate peptide Pep72

· Original indexed publication, PMID 37758480

Format: Original indexed publication, PMID 37758480 · Reviewed: Reported methods, results and evidence limitations

Original CH-1 pharmacokinetic study authors · Original indexed publication, PMID 37758480

Pep72 had very low measured blood–brain barrier permeability. The authors identified 11 main metabolites, including PGGDL and EPPTVPGGDL.

Findings, study figures and available tables

Reported findings and study design

Pep72 had very low measured blood–brain barrier permeability. The authors identified 11 main metabolites, including PGGDL and EPPTVPGGDL.

Screening of candidate peptides, permeability and transporter assays, and metabolite identification in fresh rat plasma and tissues.

Reported findings and study figures · Original indexed publication, PMID 37758480
Measure	Result	Comparison, timing and statistics
Pep72 permeability	Very low in the model used	The peptide was not identified as an efflux transporter substrate.
Metabolites	11 major structures identified	PGGDL and EPPTVPGGDL were prominent products.
Exposure details	Study-specific doses require the complete methods	No dosing equivalence to Cortexin or PPK-V.

Results concern one hydrolysate and its candidate metabolites. Similar molecular mass alone does not support a formulation match.

Source for the extracted data ↗ · Checked 2026-11-09

Population / setting: Experimental rat pharmacokinetics and cell/transport assays.
What was checked: Original indexed publication, PMID 37758480

Limitations & review scope

Results concern one hydrolysate and its candidate metabolites. Similar molecular mass alone does not support a formulation match.

Source checked 2026-11-09. See the review scope above for the material assessed.

Read the source ↗

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗